The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 601–700 of 1,006
Pusch, S., Schweizer, L., Beck, A.-C., Lehmler, J.-M., Weißert, S., Balß, J., Miller, A. K., & von Deimling, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-19 · Cited by 93
The Evolving Molecular Genetics of Low-grade Glioma
Venneti, S., & Huse, J. T. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000049 · Cited by 90
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
Mishra, P., Tang, W., Putluri, V., Dorsey, T. H., Jin, F., Wang, F., Zhu, D., Amable, L., Deng, T., Zhang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93815 · Cited by 91
Metabolic dependencies and vulnerabilities in leukemiaPreprint
Rashkovan, M., & Ferrando, A. A. (2019) · Genes & Development · doi:10.1101/gad.326470.119 · Cited by 92
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 93
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
Atlante, S., Visintin, A., Marini, E., Savoia, M., Dianzani, C., Giorgis, M., Sürün, D., Maione, F., Schnütgen, F., Farsetti, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0802-8 · Cited by 87
Cai, L., Zhu, H., Mou, Q., Wong, P. Y., Lan, L., Ng, C. W. K., Pu, L., Cheung, M. K., Wang, D., Wong, E. W. Y., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00511-x · Cited by 97
Isocitrate dehydrogenase mutations in gliomas
Guo, C., Pirozzi, C. J., Lopez, G. Y., & Yan, H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd415 · Cited by 93
The Role of Inflammation in Brain Cancer
Sowers, J. L., Johnson, K. M., Conrad, C. C., Patterson, J. T., & Sowers, L. C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_4 · Cited by 93
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in micePreprint
Akbay, E. A., Moslehi, J. J., Christensen, C. L., Saha, S. K., Tchaicha, J. H., Ramkissoon, S. H., Stewart, K. M., Carretero, J., Kikuchi, E., Zhang, H., et al. (2014) · Genes & Development · doi:10.1101/gad.231233.113 · Cited by 93
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
DNA Methylation in Cancer: A Gene Silencing Mechanism and the Clinical Potential of Its Biomarkers
Fukushige, S., & Horii, A. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.173 · Cited by 88
Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma
Chaumeil, M. M., Larson, P. E. Z., Woods, S. M., Cai, L., Eriksson, P., Robinson, A. E., Lupo, J., Vigneron, D. B., Nelson, S. J., Pieper, R. O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0680 · Cited by 87
Rare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 90
Molecular Pathways: Metabolic Control of Histone Methylation and Gene Expression in Cancer
Tran, T. Q., Lowman, X. H., & Kong, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2506 · Cited by 91
Zhang, L., Sørensen, M. D., Kristensen, B. W., Reifenberger, G., McIntyre, T. M., & Lin, F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3855 · Cited by 93
Advances in Research of Adult Gliomas
Finch, A., Solomou, G., Wykes, V., Pohl, U., Bardella, C., & Watts, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020924 · Cited by 91
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
Annotating metabolite mass spectra with domain-inspired chemical formula transformers
Goldman, S., Wohlwend, J., Stražar, M., Haroush, G., Xavier, R. J., & Coley, C. W. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00708-3 · Cited by 87
Context-dependent actions of Polycomb repressors in cancer
Koppens, M. A. J., & van Lohuizen, M. (2015) · Oncogene · doi:10.1038/onc.2015.195 · Cited by 88
Epigenetic dynamics of monocyte-to-macrophage differentiation
Wallner, S., Schröder, C., Leitão, E., Berulava, T., Haak, C., Beißer, D., Rahmann, S., Richter, A. S., Manke, T., Bönisch, U., et al. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0079-z · Cited by 84
Defining and Detecting Complex Peak Relationships in Mass Spectral Data: The Mz.unity Algorithm
Mahieu, N. G., Spalding, J. L., Gelman, S. J., & Patti, G. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01702 · Cited by 88
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
Cruz, J. V. R., Batista, C., Afonso, B. D. H., Alexandre‐Moreira, M. S., Dubois, L. G., Pontes, B., Moura‐Neto, V., & Mendes, F. A. (2022) · Cancers · doi:10.3390/cancers14133203 · Cited by 92
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A., Abbas, S., Kim, S., Ortega, M. M., Bouamar, H., Escobedo, Y. A., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 88
Self-citationEpigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Zhang, P., & Zhang, M. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00962-x · Cited by 91
The role of the histone demethylase KDM4A in cancer
Guerra-Calderas, L., González‐Barrios, R., Herrera, L. A., de León, D. F. C., & Soto‐Reyes, E. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.11.001 · Cited by 90
Bénit, P., Letouzé, É., Rak, M., Aubry, L., Burnichon, N., Favier, J., Gimenez‐Roqueplo, A., & Rustin, P. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.03.013 · Cited by 89
Cui, Q., Su, Y., Ye, P., Tian, E., Sun, G., Zhou, J., Sun, G., Liu, X., Chen, C., Murai, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10637 · Cited by 88
Dynamic DNA methylation in the brain: a new epigenetic mark for experience-dependent plasticity
Tognini, P., Napoli, D., & Pizzorusso, T. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00331 · Cited by 94
Capper, D., Simon, M., Langhans, C., Okun, J. G., Tonn, J. C., Weller, M., von Deimling, A., Hartmann, C. J., & for the German Glioma Network (2011) · International Journal of Cancer · doi:10.1002/ijc.26425 · Cited by 83
Montemurro, C., Nomoto, H., Pei, L., Parekh, V. S., Vongbunyong, K. E., Vadrevu, S., Gurlo, T., Butler, A. E., Subramaniam, R., Ritou, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10444-1 · Cited by 86
Friend or foe—IDH1 mutations in glioma 10 years on
Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 84
Perspectives on the interactions between metabolism, redox, and epigenetics in plants
Shen, Y., Issakidis‐Bourguet, E., & Zhou, D. (2016) · Journal of Experimental Botany · doi:10.1093/jxb/erw310 · Cited by 89
Chen, F., Bian, K., Tang, Q., Fedeles, B. I., Singh, V., Humulock, Z. T., Essigmann, J. M., & Li, D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00009 · Cited by 91
Mukherjee, J., Johannessen, T.-C. A., Ohba, S., Chow, T. T., Jones, L. E., Pandita, A., & Pieper, R. O. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2269 · Cited by 87
Kalinina, J., Carroll, A., Wang, L., Yu, Q., Mancheno, D. E., Wu, S., Liu, F., Ahn, J. Y., He, M., Mao, H. Z., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0888-x · Cited by 84
Chicken or the egg: Warburg effect and mitochondrial dysfunction
Senyilmaz, D., & Teleman, A. A. (2015) · F1000Prime Reports · doi:10.12703/p7-41 · Cited by 89
Badur, M. G., Muthusamy, T., Parker, S. J., Ma, S., McBrayer, S. K., Cordes, T., Magaña, J. H., Guan, K., & Metallo, C. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.074 · Cited by 87
Self-citationEpigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 90
IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabölen, A., Yilmaz, E., & Onder, T. B. (2021) · Biomedicines · doi:10.3390/biomedicines9070799 · Cited by 88
Iqbal, J., Wilcox, R., Naushad, H., Rohr, J. M., Heavican, T. B., Wang, C., Bouska, A. C., Fu, K., Chan, W. C., & Vose, J. M. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.003 · Cited by 83
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer
Li, J., He, Y., Tan, Z., Lu, J., Li, L., Song, X., Shi, F., Xie, L., You, S., Luo, X., et al. (2018) · Theranostics · doi:10.7150/thno.21524 · Cited by 85
Melanoma epigenetics: novel mechanisms, markers, and medicines
Lee, J. J., Murphy, G. F., & Lian, C. G. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.87 · Cited by 85
Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
Appin, C., & Brat, D. J. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000048 · Cited by 86
Epigenetic Therapies for Osteoarthritis
Grandi, F. C., & Bhutani, N. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.008 · Cited by 85
Casalino, L., & Verde, P. (2020) · Genes · doi:10.3390/genes11080922 · Cited by 83
Mitochondrial Metabolism in Carcinogenesis and Cancer Therapy
Moindjie, H., Rodrigues, S., & Nahmias, C. (2021) · Cancers · doi:10.3390/cancers13133311 · Cited by 88
Control of histone demethylation by nuclear-localized α-ketoglutarate dehydrogenase
Huang, F., Luo, X., Ou, Y., Gao, Z., Tang, Q., Chu, Z., Zhu, X., & He, Y. (2023) · Science · doi:10.1126/science.adf8822 · Cited by 84
Lin, C., Hou, H., Chou, W., Kuo, Y., Liu, C., Chen, C., Lai, Y.-J., Tseng, M., Huang, C., Chiang, Y., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23596 · Cited by 85
R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
Ye, D., Ma, S., Xiong, Y., & Guan, K. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.005 · Cited by 83
Self-citationInteractions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Dickson, K. M., Gustafson, C. B., Young, J. I., Zuchner, S. L., & Wang, G. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.010 · Cited by 81
Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 85
Oncometabolites in Cancer: Current Understanding and Challenges
Liu, Y., & Yang, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3730 · Cited by 83
Self-citationD-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 87
Self-citationDNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 89
Shigeta, K., Hasegawa, M., Hishiki, T., Naito, Y., Baba, Y., Mikami, S., Matsumoto, K., Mizuno, R., Miyajima, A., Kikuchi, E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022110620 · Cited by 82
Metabolic Reprogramming in Mutant IDH1 Glioma Cells
Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 90
Mulholland, S. A., Pearson, D. M., Hamoudi, R., Malley, D. S., Smith, C. M., Weaver, J. M. J., Jones, D., Kocialkowski, S., Bäcklund, L. M., Collins, V. P., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26499 · Cited by 81
Tang, S., Fang, Y., Huang, G., Xu, X., Padilla‐Banks, E., Fan, W., Xu, Q., Sanderson, S. M., Foley, J. F., Dowdy, S., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796708 · Cited by 81
Novel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 82
Kristensen, L. H., Nielsen, A. L., Helgstrand, C., Lees, M. J., Cloos, P. A., Kastrup, J. S., Helin, K., Olsen, L., & Gajhede, M. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08567.x · Cited by 81
Geisenberger, C., Möck, A., Warta, R., Rapp, C., Schwager, C., Korshunov, A., Nied, A.-K., Capper, D., Brors, B., Jungk, C., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1427-y · Cited by 78
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases
Tarhonskaya, H., Rydzik, A. M., Leung, I. K. H., Loik, N. D., Chan, M. C., Kawamura, A., McCullagh, J. S. O., Claridge, T. D. W., Flashman, E., & Schofield, C. J. (2014) · Nature Communications · doi:10.1038/ncomms4423 · Cited by 80
Brito, C., Azevedo, A., Esteves, S., Marques, A. R., Martins, C., Costa, I., Mafra, M., Marques, J. B., Roque, L., & Pojo, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-6177-0 · Cited by 80
de la Fuente, M. I., Colman, H., Rosenthal, M. A., Tine, B. A. V., Levacic, D., Walbert, T., Gan, H. K., Vieito, M., Milhem, M. M., Lipford, K., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac139 · Cited by 82
Biomarker-driven diagnosis of diffuse gliomas
Appin, C., & Brat, D. J. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.05.002 · Cited by 84
Jeffery, C. J. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.10.003 · Cited by 83
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
A Cell‐Permeable Ester Derivative of the JmjC Histone Demethylase Inhibitor IOX1
Schiller, R., Scozzafava, G., Tumber, A., Wickens, J. R., Bush, J. T., Rai, G., Lejeune, C., Choi, H., Yeh, T., Chan, M. C., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300428 · Cited by 81
Autophagy and oxidative stress in gliomas with IDH1 mutations
Gilbert, M. R., Liu, Y., Neltner, J. H., Pu, H., Morris, A. J., Sunkara, M., Pittman, T. A., Kyprianou, N., & Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1194-6 · Cited by 78
Self-citationDysregulated glycolysis as an oncogenic event
Mikawa, T., LLeonart, M. E., Takaori‐Kondo, A., Inagaki, N., Yokode, M., & Kondoh, H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1840-3 · Cited by 85
Berretta, M., Cavaliere, C., Alessandrini, L., Stanzione, B., Facchini, G., Balestreri, L., Perin, T., & Canzonieri, V. (2016) · Oncotarget · doi:10.18632/oncotarget.13929 · Cited by 79
Cancer progression is mediated by proline catabolism in non-small cell lung cancer
Liu, Y., Mao, C., Wang, M., Liu, N., Ouyang, L., Liu, S., Tang, H., Cao, Y., Liu, S., Wang, X., et al. (2020) · Oncogene · doi:10.1038/s41388-019-1151-5 · Cited by 79
Self-citationCorona, G., Rizzolio, F., Giordano, A., & Toffoli, G. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.24003 · Cited by 79
Liang, D., Liu, H., Yang, C., Jaing, T., Hung, I., Yeh, T., Chen, S., Hou, J., Huang, Y., Shih, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436782 · Cited by 81
Self-citationLi, H., Chawla, G., Hurlburt, A. J., Sterrett, M. C., Zaslaver, O., Cox, J. E., Karty, J. A., Rosebrock, A. P., Caudy, A. A., & Tennessen, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614102114 · Cited by 76
Bai, M., Yang, L., Liao, H., Liang, X., Xie, B., Xiong, J., Tao, X., Chen, X., Cheng, Y., Chen, X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0360-7 · Cited by 80
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78
Self-citationInhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
Wu, F., Jiang, H., Zheng, B., Kogiso, M., Yao, Y., Zhou, C., Li, X., & Song, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00684 · Cited by 78
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B. G., Intlekofer, A. M., Ahn, J., SHANK, K. R., Rapaport, F. T., Patel, M. A., Papalexi, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94516 · Cited by 81
Altering 5-hydroxymethylcytosine modification impacts ischemic brain injury
Miao, Z., He, Y., Xin, N., Sun, M., Chen, L., Lin, L., Li, J., Kong, J., Jin, P., & Xu, X. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv307 · Cited by 78
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Metabolic regulation of stem cell function
Burgess, R., Agathocleous, M., & Morrison, S. J. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12247 · Cited by 81
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
Sirtuins in Metabolic and Epigenetic Regulation of Stem Cells
Fang, Y., Tang, S., & Li, X. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.12.002 · Cited by 79
A Tale of Metabolites: The Cross-Talk between Chromatin and Energy Metabolism
Martínez-Pastor, B., Cosentino, C., & Mostoslavsky, R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0059 · Cited by 76
Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells
Pecqueur, C., Oliver, L., Oizel, K., Lalier-Bretaudeau, L., & Vallette, F. M. (2013) · International Journal of Cell Biology · doi:10.1155/2013/805975 · Cited by 83
Genetic and epigenetic alterations of myeloproliferative disorders
Feenstra, J. D. M., & Královics, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1235-2 · Cited by 81
5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer
Uribe‐Lewis, S., Stark, R., Carroll, T. D., Dunning, M., Bachman, M., Ito, Y., Stojic, L., Halim, S., Vowler, S. L., Lynch, A. G., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0605-5 · Cited by 75
Cardioprotection by nicotinamide mononucleotide (NMN): Involvement of glycolysis and acidic pH
Nadtochiy, S. M., Wang, Y. T., Nehrke, K. W., Munger, J., & Brookes, P. S. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.06.007 · Cited by 75
Operation of a TCA cycle subnetwork in the mammalian nucleus
Kafkia, E., Andrés‐Pons, A., Ganter, K., Seiler, M., Smith, T. S., Andrejeva, A., Jouhten, P., Pereira, F. M., Franco, C., Kuroshchenkova, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq5206 · Cited by 76
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 78
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Xia, L., Wu, B., Fu, Z., Fěng, F., Qiao, E., Li, Q., Sun, C., & Ge, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4008 · Cited by 80
Nagashima, H., Tanaka, K., Sasayama, T., Irino, Y., Sato, N., Takeuchi, Y., Kyotani, K., Mukasa, A., Mizukawa, K., Sakata, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now090 · Cited by 76
Current State and Future Prospects of Immunotherapy for Glioma
Kamran, N., Alghamri, M. S., Núñez, F. J., Shah, D., Asad, A. S., Candolfi, M., Altshuler, D. B., Lowenstein, P. R., & Castro, M. G. (2018) · Immunotherapy · doi:10.2217/imt-2017-0122 · Cited by 77
Carella, A., Tejedor, J. R., García, M. G., Urdinguio, R. G., Bayón, G. F., Sierra, M., López, V., Toraño, E. G., Santamarina‐Ojeda, P., Pérez, R. F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32520 · Cited by 77
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
